---
schema_version: "secwatch.filing_event.v1"
accession: "0001100682-26-000142"
form_type: "8-K"
ticker: "CRL"
cik: "0001100682"
company_name: "CHARLES RIVER LABORATORIES INTERNATIONAL, INC."
filed_at: "2026-09-24T12:12:10+00:00"
generated_at: "2026-09-24T13:03:41.814214+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Charles River unveils 'Pathway to Purpose' strategy; reaffirms 2026 guidance at upper end

## Summary
- Announces 'Pathway to Purpose' strategy focused on modernization, scientific portfolio, and client-centric approach.
- Expects over $300M cumulative savings from Create the Future program (2027-2030) via automation and AI digital tools.
- Reaffirms 2026 guidance: organic revenue growth at upper end of 0%–1%; non-GAAP EPS at upper end of $11.15–$11.45.
- Introduces 2030 targets: 5%–7% organic revenue CAGR, ~24% non-GAAP operating margin, low-double-digit EPS CAGR.
- Bioanalysis revenue targeted at ~$450M by 2030; Apollo platform now serves 18,000 client users.

## SEC filing metadata
- accession: 0001100682-26-000142
- form_type: 8-K
- ticker: CRL
- cik: 0001100682
- company_name: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- filed_at: 2026-09-24T12:12:10+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1100682/000110068226000142/0001100682-26-000142-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1100682/000110068226000142/crl-20260924.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001100682-26-000142
- JSON: https://secwatch.observer/filing/0001100682-26-000142.json
- Plain text: https://secwatch.observer/filing/0001100682-26-000142.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.